[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-349683-105":59,"doc-detail-349683-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","a-phase-ii-trial-to-evaluate-the-safety-and-immunogenicity-of-two-doses-of-a-folate-receptor-alpha-vaccine-in-patients-with-triple-negative-breast-cancer","A Phase II Trial to Evaluate the Safety and Immunogenicity of Two Doses of a Folate Receptor Alpha Vaccine in Patients with Triple-Negative Breast Cancer","","A randomized phase II trial evaluated safety and immune responses to a folate receptor alpha (FRα) vaccine using two dosing regimens in patients with triple-negative breast cancer. Patients received either low-dose (825 μg) or high-dose (2.5 mg) FRα vaccine peptides plus GM-CSF across six 4-week cycles, with or without cyclophosphamide (CP) pretreatment. Eighty patients were dosed and 58 were evaluable for immunogenicity; vaccination was well tolerated and induced immunity in 83% with persistent FRα-specific CD4 T cells. No dose or CP-related differences in immunity were observed, and no disease-related deaths occurred. ",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/a-phase-ii-trial-to-evaluate-the-safety-and-immunogenicity-of-two-doses-of-a-folate-receptor-alpha-vaccine-in-patients-with-triple-negative-breast-cancer/349683/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/a-phase-ii-trial-to-evaluate-the-safety-and-immunogenicity-of-two-doses-of-a-folate-receptor-alpha-vaccine-in-patients-with-triple-negative-breast-cancer/349683.png","ImageObject",300,407,{"name":92,"@type":93},"Logic","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-30","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":34},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What was the purpose of this phase II trial?","Question",{"text":112,"@type":113},"To evaluate the safety and immunogenicity of two doses of a folate receptor alpha (FRα) vaccine in triple-negative breast cancer patients, including testing with or without cyclophosphamide (CP) pretreatment.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How were patients treated in the study?",{"text":117,"@type":113},"Patients who completed prior therapies received either low-dose or high-dose FRα vaccine peptides plus GM-CSF in six 4-week cycles, with or without CP before vaccination.",{"name":119,"@type":110,"acceptedAnswer":120},"What were the main immunogenicity findings?",{"text":121,"@type":113},"Vaccination was well tolerated and induced immunity in 83% of patients, with high, persistent FRα-specific T cells comparable to responses against tetanus toxoid; no differences were seen between the two doses or with CP pretreatment.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},349683,1790173044,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":34,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":41,"preview_page_count":19,"preview_urls":145},1099513958762,"https://ap-avatar.wpscdn.com/avatar/1000023916a998db790?x-image-process=image/resize,m_fixed,w_180,h_180&k=1784791008015729253","A Phase II Trial to Evaluate the Safety and Immunogenicity of Two Doses of a Folate Receptor Alpha Vaccine in Patients with Triple-Negative Breast Cancer  \nKeith L. Knutson1,2, Hala Abu-Fares1, Patricia Keating3, Matthew S. Block4,5, Nadine Norton2, Courtney L. Erskine5, Davitte Cogen1, Hadeel Assad6, Stephanie L. Graff7, Erika P. Hamilton8, Hyo S. Han9, Kristi J. McIntyre10, Aziza Nassar11, Joseph A. Sparano12, Amy Tiersten13, Katherine H. Tkaczuk14, Patrick J. Ward15, Glynn Wilson16, Gerald Garrett16,17, Richard T. Kenney16,17, and Priyanka Sharma18  \n|  |  | A |  | B | S |  | T | R |  | A |  | C | T |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |\n| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |\n|  | Purpose: CD4 T-cell immunity is associated with improved survival in patients with breast cancer. We previously reported a phase I trial evaluating a folate receptor alpha (FRα) vaccine administered with cyclophosphamide (CP), demonstrating excellent safety and immunogenicity. To simplify the vaccine strategy for ease of use, we report here the results of a randomized phase II trial evaluating a lower vaccine dose alongside the original dose, administered with or without CP pretreatment.\u003Cbr>Patients and Methods: Patients with triple-negative breast cancer who completed all systemic and local therapies were assigned to receive either low-dose (825 μg) or high-dose (2.5 mg) vaccine peptides plus GM-CSF in six 4-week cycles, with or without CP prior to vaccination. Safety was monitored, and immunogenicity was evaluated before and after vaccination.\u003Cbr>􀀶 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | Results: A total of 80 patients were dosed with vaccine, and 58 patients were evaluable for immunogenicity. Vaccination was well tolerated and elicited immunity in 83% of patients. Levels of FRα-specific T cells were high, persistent, and comparable with T-cell levels against tetanus toxoid. No differences in immunity were observed between the two doses. CP pretreatment also did not affect the immune responses. Recurrences occurred in eight evaluable patients and were unrelated to the treatment arm. No patients died during the study because of their disease.\u003Cbr>Conclusions: The reduced-dose FRα vaccine is as effective asthe original dose and does not require CP to generate maximal immunity. These findings may inform the design of trials testing efficacy in triple-negative breast cancer or other cancers. |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |\n\nIntroduction  \nTriple-negative breast cancer (TNBC) represents one of the most aggressive subtypes of breast cancer, defined by the absence of  \n1Department of Immunology, Mayo Clinic, Jacksonville, Florida. 2Department of Cancer Biology, Mayo Clinic, Jacksonville, Florida. 3Department of Biological Sciences, Florida Atlantic University, Boca Raton, Florida. 4Department of Oncology, Mayo Clinic, Rochester, Minnesota. 5Department of Immunology, Mayo Clinic, Rochester, Minnesota. 6Karmanos Cancer Institute, Detroit, Michigan. 7Research Medical C","cbCaimDRLFZlue8m","https://ap.wps.com/l/cbCaimDRLFZlue8m","pdf",3559768,12,"English","# Purpose\n## Patients and Methods\n## Results\n## Conclusions\n# Introduction","[{\"question\":\"What was the purpose of this phase II trial?\",\"answer\":\"To evaluate the safety and immunogenicity of two doses of a folate receptor alpha (FRα) vaccine in triple-negative breast cancer patients, including testing with or without cyclophosphamide (CP) pretreatment.\"},{\"question\":\"How were patients treated in the study?\",\"answer\":\"Patients who completed prior therapies received either low-dose or high-dose FRα vaccine peptides plus GM-CSF in six 4-week cycles, with or without CP before vaccination.\"},{\"question\":\"What were the main immunogenicity findings?\",\"answer\":\"Vaccination was well tolerated and induced immunity in 83% of patients, with high, persistent FRα-specific T cells comparable to responses against tetanus toxoid; no differences were seen between the two doses or with CP pretreatment.\"}]","A Phase II Trial to Evaluate the Safety and Immunogenicity of Two Doses of a Folate Receptor Alpha Vaccine in Patients with Triple-Negative Breast Cancer | PDF",1790085016,[146,150,154,158],{"page_no":8,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/87ba3ca7371ef89f440844cb82c5f7a8.webp",983,1315,{"page_no":14,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/eccedf5be3afa38a5f2d1bae57c1b25f.webp",982,1314,{"page_no":81,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/50f0ae02b23d86257f374468650bc9fa.webp",981,1312,{"page_no":19,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/c53edec341d3480aa12b2ebe9c7ffca4.webp",980,1311]